Tomas Navratil, Chief Development Officer, on August 28, 2026, sold 13,744 shares in Glaukos (GKOS) for $2,483,104. Following the Form 4 filing with the SEC, Navratil has control over a total of 73,890 common shares of the company, with 73,890 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1192448/000192005326000026/xslF345X05/ownership.xml
Olivier Le Peuch, Director, Chief Executive Officer, on September 01, 2026, sold 35,000 shares in SLB (SLB) for $2,100,000. Following the Form 4 filing with the SEC, Le Peuch has control over a total of 1,296,328 common shares of the company, with 1,296,328 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/87347/000008734726000122/xslF345X05/form4.xml
Brian Michael Bonnell, Chief Financial Officer, on September 01, 2026, sold 6,381 shares in ICU Medical (ICUI) for $1,116,675. Following the Form 4 filing with the SEC, Bonnell has control over a total of 56,062 common shares of the company, with 56,062 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/883984/000180483126000006/xslF345X05/edgardoc.xml
Leonard M Tannenbaum, 10% Owner, Director, on August 28, 2026, executed a purchase for 119,025 shares in Advanced Flower Capital (AFCG) for $423,887. Following the Form 4 filing with the SEC, Tannenbaum has control over a total of 7,241,383 common shares of the company, with 6,834,076 shares held directly and 407,307 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1822523/000162828026059909/xslF345X05/wk-form4_1788296554.xml